Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Revises Definition of Promotion in Code of Practice
The Japan Pharmaceutical Manufacturers Association (JPMA) on May 23 announced the first update in six years of its Code of Practice (COP), revising the definition of “promotion” to make it consistent with global and other relevant guidelines. This will mark…
To read the full story
Related Article
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
ORGANIZATION
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
- FPMAJ Sets Up Drug Security Task Force under Chairman
July 3, 2026
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…